<DOC>
	<DOCNO>NCT02788474</DOCNO>
	<brief_summary>Identifying biomarkers predict clinical course benefit therapy early course disease remain one urgent relevant challenge improve overall patient management , prevent treatment delay overtreatment . This study conduct examine effect nintedanib treatment change biomarkers indicative extracellular matrix turnover show recently correlate disease progression . This study aim confirm association biomarker course first three month treatment disease progression .</brief_summary>
	<brief_title>Effect Nintedanib Biomarkers Extracellular Matrix Turnover Patients With Idiopathic Pulmonary Fibrosis Limited Forced Vital Capacity Impairment</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Inclusion criterion : Written inform consent consistent International Conference Harmonisation Good Clinical Practice local law , sign prior participation trial include study relate procedure perform ; Male female patient age &gt; =40 year Visit 1 ; A clinical diagnosis Idiopathic pulmonary fibrosis ( IPF ) within last 3 year visit 0 , base upon American Thoracic Society/ European Respiratory Society /Japanese Respiratory Society/ Latin American Thoracic Association 2011 guideline ; Chest high resolution compute tomography ( HRCT ) scan perform within 18 month Visit 0 ; Combination HRCT pattern , surgical lung biopsy pattern ( latter available ) assess central review consistent diagnosis Idiopathic pulmonary fibrosis ; Forced vital capacity ( FVC ) &gt; =80 % predict normal Visit 1 . Exclusion criterion : Alanine transaminase , Aspartate aminotransferase &gt; 1.5 fold upper limit normal ( ULN ) Visit 1 ; Total bilirubin &gt; 1.5 fold ULN Visit 1 ; Patients underlie chronic liver disease ( Child Pugh A , B C hepatic impairment ) ; Relevant airways obstruction , i.e . prebronchodilator Forced expiratory volume 1 second / Forced vital capacity &lt; 0.70 ; History myocardial infarction within 6 month visit 1 unstable angina within 1 month Visit 1 ; Bleeding Risk : Known genetic predisposition bleeding ; Patients require fibrinolysis , fulldose therapeutic anticoagulation high dose antiplatelet therapy ; History haemorrhagic central nervous system ( CNS ) event within 12 month prior Visit 1 ; History haemoptysis haematuria , active gastrointestinal bleeding ulcer and/or major injury surgery within 3 month prior Visit 1 ; International normalise ratio ( INR ) &gt; 2 Visit 1 ; Prothrombin time ( PT ) partial thromboplastin time ( PTT ) &gt; 150 % ULN Visit 1 ; Planned major surgery trial participation , include lung transplantation , major abdominal major intestinal surgery ; History thrombotic event ( include stroke transient ischemic attack ) within 12 month Visit 1 ; Creatinine clearance &lt; 30 mL/min calculate CockcroftGault formula Visit 1 ; Treatment nintedanib , pirfenidone , azathioprine , cyclophosphamide , cyclosporine , investigational drug , nacetylcysteine , prednisone/prednisolone &gt; 15 mg daily &gt; 30 mg every 2 day OR use systemic corticosteroid well investigational drug within 4 week Visit 2 ; Known hypersensitivity nintedanib , peanut , soya component study medication ; Prior discontinuation nintedanib treatment due intolerability/ adverse event consider drug relate ; A disease condition opinion investigator may interfere test procedure put patient risk participate trial ; Alcohol drug abuse opinion treat physician would interfere treatment would affect patient 's ability participate trial ; Patients able understand follow study procedure limit home spirometry , include completion selfadministered questionnaire without help ; Women pregnant , nursing , plan become pregnant trial female patient positive pregnancy ( ÃŸHCG ) test Visit 1 and/or Visit 2 ; Women childbearing potential4 willing able use highly effective method birth control per ICH M3 ( R2 ) result low failure rate le 1 % per year use consistently correctly . Patients acute IPF exacerbation respiratory tract infection four week prior Visit 1 screen period ; Patients participate another trial investigational drug/s within one month prior Visit 1 patient previously enrol trial ; Further exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>